Knockout studies in AD mouse models have shown that the absence of PCSK9 reduced Aβ deposition and neuroinflammation, suggesting its potential as a dual therapeutic target for managing metabolic and inflammatory pathways in AD [66]. The gene discussed is PCSK9; the disease is Alzheimer disease.